logo
Plus   Neg
Share
Email

CVS Health Boosts FY20 Outlook - Quick Facts

While reporting financial results for the second quarter on Wednesday, CVS Health Corp. (CVS) raised its earnings and adjusted earnings guidance for the full-year 2020, reflecting an update to its estimated full year effective income tax rate.

For fiscal 2020, the company now projects earnings in a range of $5.59 to $5.72 per share and adjusted earnings in a range of $7.14 to $7.27 per share.

Previously, the company expected earnings in the range of $5.47 to $5.60 per share and adjusted earnings in the range of $7.04 to $7.17 per share.

On average, 26 analysts polled by Thomson Reuters expect the company to report earnings of $7.16 per share for the year. Analysts' estimates typically exclude special items.

The Company projects higher utilization in its Health Care Benefits segment in the second half of 2020 than in the first half of 2020 and continued significant COVID-19 related investments, including operating costs, in the remainder of the year.

Further, the company also raised its full year cash flow from operations guidance range to $11.0 billion to $11.5 billion from $10.5 billion to $11.0 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite the coronavirus pandemic, retailers are prepared for an early start to the holiday shopping season by offering discounts earlier so that consumers can buy and receive the gifts they want in time, the National Retail Federation or NRF said. The NRF also said it is launching a nationwide consumer education campaign called "New Holiday Traditions". Facebook (FB) has revealed new messaging features for Instagram, which will make it easier for users to stay in touch with others across Facebook's family of apps. The main change is that people using the Messenger app can now reach Instagram users, and vice versa. The users can control where they receive... Regeneron Pharmaceuticals, Inc. announced positive first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 in COVID-19 patients. REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients. The company said it plans rapidly to discuss results with regulatory authorities.
Follow RTT